secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K/A
Filed at:   2026-09-08T21:29:33+00:00
Accession:  0001493152-26-041807
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos exchanges $2.86M Streeterville debt for 11.45M shares, 52% dilution
-------------------------------------------------------------------------

- Exchanged $2,861,270 of Streeterville Note principal for 11,445,080 common shares (avg $0.25/share) on Sept 2, 2026.
- Shares represent ~52% of pre-exchange outstanding (22,164,313) and ~34% of post-exchange (33,609,393).
- Following exchanges, Streeterville Note balance reduced to $3.7 million; no cash proceeds received.
- Exchanges done via 12 agreements; shares unregistered, issued under Section 3(a)(9).
- Amendment corrects original 8-K report date to Sept 2, 2026; transactions consummated that date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226041807/0001493152-26-041807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226041807/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer